Related to Altravax Awarded $3.45M from NIAID for HIV-1 Vaccine Research

• Pevion to Use Cevec’s Protein-Expression Technology for Infectious Disease Vaccine
  
• Cytheris Scores €12M Financing to Progress IL-7 Pipeline
  
• Crucell and J&J to Develop RSV Vaccine
  
• NIH Bankrolls Six Centers with $100M to Characterize Human Immune Responses
  
• Emergent Wins $28.7M NIAID Contract for Development of Third-Gen Anthrax Vaccine
  
• Okairos Obtains €16M to Advance T-Cell Vaccines for Infectious Diseases
  
• J&J and Crucell in Advanced Negotiations for €1.75B Acquisition Deal
  
• GenVec Receives Second-Year Funding from SAIC for HIV and Flu Vaccine Development
  
• MedImmune Nabs Rights to IDC’s GLA Adjuvant for Infectious Disease Vaccines
  
• Inviragen and Duke-NUS Form Vaccine Partnership to Tackle Emerging Infectious Diseases
  
• IAVI Partners with Indian Government Institute for Broad-Spectrum HIV Vaccine Initiative
  
• Crucell to Use Pepscan’s CLIPS Technology for Development of Infectious Disease Vaccines
  
• Institute of Human Virology Awarded $23.4M to Fund Clinical Trials of HIV Vaccine
  
• $3M NIAID Grant Will Fund Inviragen Collaboration with UTMB to Develop Chikungunya Vaccine
  
• GeoVax Receives Latest Tranche of $19.6M NIAID Funding for HIV Vaccine
  
• Horizon Licenses X-Man Panel for Viral Diseases and Leukemias from the University of Minnesota
  
• CSL Negotiates Option to Pevion’s Candida Vaccine for Australia and New Zealand
  
• GeoVax Labs Receives $0.8M Funding Boost from NIAID to Progress HIV Vaccine
  
• GeoVax and Vivalis Sign Deal for the Biomanufacture of MVA HIV Vaccine in EB66 Cells
  
• CureVac, Sanofi Pasteur, and In-Cell-Art Collaborate on €33.1M DARPA-Supported Vaccine Program